Algernon Receives Clearance From Health Canada for Ifenprodil COVID-19 Phase 2b/3 Multinational Clinical Trial (Globe Newswire)

Algernon Receives Clearance From Health Canada for Ifenprodil COVID-19 Phase 2b/3 Multinational Clinical Trial

UF startup Algernon Pharmaceuticals Inc., a clinical-stage pharmaceutical development company, is pleased to announce that it has received a “No Objection” letter from Health Canada to proceed with NP-120 (Ifenprodil) COVID-19 Phase 2b/3 multinational clinical trial. The same study protocol is being prepared for submission to the U.S. FDA and Australian regulatory authorities.

“The study is an adaptive pilot to pivotal trial design based on guidance documents from the World Health Organization (WHO) to determine if Ifenprodil can improve clinical symptoms of COVID-19 by reducing the number of COVID-19 diagnosed patients from progressing to mechanical ventilation with intubation and death,” said Dr. Mark Williams, Algernon’s CSO.

Learn more about Algernon Receives Clearance From Health Canada for Ifenprodil COVID-19 Phase 2b/3 Multinational Clinical Trial.
Related news Algernon Submits Application to Health Canada for Ifenprodil COVID-19 Phase 2b/3 Multinational Clinical Trial.
X